All In Biotech

BLA 761484 · Janssen Biotech

Rybrevant Faspro

Amivantamab and Hyaluronidase-Lpuj · Single-Use

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Feb 13, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

52

8 Phase 3, 19 recruiting

FAERS reports

306

207 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 13, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
4 products under this application
  • RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 2,400MG/30,000 UNITS PER 15ML · VIAL, SINGLE-USE · Prescription
  • RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 1,600MG/20,000 UNITS PER 10ML · VIAL, SINGLE-USE · Prescription
  • RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 3,5200MG/44,000 UNITS PER 22ML · VIAL, SINGLE-USE · Prescription
  • RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 2,240MG/28,000 UNITS PER 14ML · VIAL, SINGLE-USE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amivantamab" as an intervention, any sponsor and status, largest first.

All 52 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash47
  • infusion related reaction32
  • paronychia29
  • off label use22
  • nausea17
  • stomatitis17
  • pyrexia14
  • administration related reaction13
  • decreased appetite13
  • pruritus12
  • cytopenia11
  • fatigue11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20251
2026305

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 53 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.